HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /
2024-09-11 2:45:02 PM | Chg. +0.020 | Volume | Bid2:49:00 PM | Ask2:49:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2.400EUR | +0.84% | - Turnover: - |
2.410Bid Size: 1,245 | 2.450Ask Size: 1,224 | 84.41 mill.EUR | 0.00% | - |
GlobeNewswire
2017-11-16
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-02-05
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
2006-10-09
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients